asco.org2d
Career Development
ASCO is committed to providing members with lifelong learning and training opportunities through an array of Professional Development programs and activities. ASCO’s distinct leadership programs are ...
asco.org3d
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org4d
Funding Opportunities
Our grants and awards support basic, translational and clinical cancer research done by gifted physician-scientists at every stage of their careers, from the best and brightest among young ...
asco.org4d
For PR Professionals
This page contains important information for corporate and institutional public relations professionals about ASCO Meetings. Once an abstract is submitted to an ASCO Meeting, the abstract and study ...
asco.org5d
Young Investigator Award
The Conquer Cancer Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this award is to fund ...
asco.org5d
Young Investigator Award Special Competitions
The Conquer Cancer Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. YIA Special Competitions are open in ...
asco.org5d
News & Initiatives
To improve patient care, ASCO advocates for increased federal funding for research, greater health care access, value in cancer care, and payment reform.